Company news

Castle Biosciences, Inc. news in 2021

Castle Biosciences, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Castle Biosciences Completes Acquisition of Cernostics

December 5, 2021

Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio

November 23, 2021

Castle Biosciences Announces Third Quarter 2021 Results

November 7, 2021

Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm

November 4, 2021

Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System

November 3, 2021

DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence

October 27, 2021

Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021

October 24, 2021

Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021

October 21, 2021

Castle Biosciences to Acquire Cernostics

October 18, 2021

Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma

September 15, 2021

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

August 23, 2021

Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting

August 15, 2021

Castle Biosciences Announces Second Quarter 2021 Results

August 8, 2021

Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting

August 5, 2021

Castle Biosciences Collaborates with the Melanoma Research Foundation

August 1, 2021

Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021

July 25, 2021

Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

July 22, 2021

Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021

July 21, 2021

Castle Biosciences Expands its Board of Directors with New Appointments

July 15, 2021

Castle Biosciences Announces Receipt of New York Laboratory Permit

June 8, 2021

Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters

May 23, 2021

Castle Biosciences Supports the American Skin Association with Research Grant

May 20, 2021

Castle Biosciences Announces First Quarter 2021 Results

May 9, 2021

Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.

May 3, 2021

Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory

April 26, 2021

Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021

April 25, 2021

Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population

April 22, 2021

Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma

April 12, 2021

Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions

March 24, 2021

Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results

March 7, 2021

Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021

February 21, 2021

Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference

January 19, 2021

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results

January 12, 2021

Calls in 2021

Decks in 2021